Findings from a retrospective study identified risk factors for thrombosis in patients with post-polycythemia vera myelofibrosis, compared with patients with polycythemia vera.
A team of researchers presented their strategies for choosing patients with myelofibrosis who may be candidates for allogeneic stem cell transplantation and guiding their treatment.
A case study highlights a potential adverse effect of prolonged hydroxyurea therapy in a patient with polycythemia vera.
Researchers sought to determine the prevalence of frailty among patients with myeloproliferative neoplasms.
Analysis of data from 2 clinical trials sought to determine the effect on symptom burden of 2 common therapies for myeloproliferative neoplasms.
Researchers sought to determine the effect of diagnosis and treatment on response to COVID-19 vaccination among patients with myeloproliferative neoplasms.
As myeloproliferative neoplasms (MPN) are a particularly rare form of blood cancer without a clear cause, it may be difficult to understand how lifestyle factors can affect both MPN risk and symptom burden. What has research suggested about the ways certain lifestyle factors affect MPNs?
Multivariate analysis of patients with MPNs receiving antiplatelet or anticoagulation therapy revealed an increase in risk of bleeding events in these patients.
Two cases are presented to illustrate that DOACs are not efficacious in MPN-associated portal hypertension after TIPS procedure.
Investigators assessed studies for evidence to guide the management of MPN in patients with COVID-19.
